EUVIMEDEUVIMED entdecken
Crossref

Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures

Yi Liu iD, Dalia Walzer, Sarah Schmitz, Alpana P Shukla, Xiaoyue Ma, Dawn Chirko, Ilissa Pipia, Swetha Sathi, Uthman Shukairy, Michael Greenberg, Sangeeta R Kashyap, Emily M Stein

The Journal of Clinical Endocrinology & Metabolism · 17.06.2026 · 111 (7) · 1959-1966

DOI: 10.1210/clinem/dgag052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.02.2026. Verfasst von Yi Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, New York, N…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Bone Density, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Glucagon-like peptide-1 receptor agonists (GLP1-RA) have potent glucose-lowering and weight loss benefits, but their effects on bone remain unclear.

Objective

To investigate changes in bone mineral density (BMD) in patients using semaglutide (SEM) and tirzepatide (TIR), a dual agonist of GLP-1/glucose dependent insulinotropic polypeptide.

Methods

Single-center retrospective study. Adult patients using SEM/TIR for ≥6 months with DXA scans before initiation and at least 6 months after were matched by age, sex, BMI, and diabetes mellitus (DM) to nonusers with at least 2 DXA scans over the same period. The primary outcome was the percentage change in total hip (TH) BMD.

Results

We included 255 patients using SEM or TIR in the GLP-1 RA group (92% female, mean age 64 ± 9 years, BMI 31.0 ± 5.6 kg/m²) and 255 controls. After a median follow-up of 17 months, the GLP-1 RA group achieved a median 5% weight loss. Both groups had significant declines in BMD at TH and FN, with a similar magnitude between groups. In the GLP-1RA group, weight loss was directly associated with bone loss at the TH and FN (r = 0.32 for TH, r = 0.17 for FN, both P < .01). Among patients without DM, greater TH bone loss was noted in the GLP-1 RA group compared to controls (−1% vs −0.6%, P = .04), whereas TH bone loss was similar between groups among patients with DM.

Conclusion

SEM/TIR use was associated with greater annualized TH bone loss in patients without DM, whereas TH bone loss was comparable between GLP-1 RA and controls in patients with DM. These findings suggest GLP-1 RA's effects on bone may differ by DM status, with weight loss driving bone loss in patients without DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesBone DensityDiabetes Mellitus, Type 2Hypoglycemic AgentsFractures, BoneHumansTirzepatideSemaglutideFemaleMaleMiddle AgedRetrospective StudiesAgedGlucagon-Like Peptide-1 Receptor AgonistsWeight LossFollow-Up Studies

Stichwörter der Autor:innen

bone lossdiabetesobesityosteoporosissemaglutidetirzepatide

Substanzen

TirzepatideSemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY 10021, USA.
  • Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY 10021, USA.
  • Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medical College, New York, NY 10021, USA.
  • Division of Endocrinology, Hospital for Special Surgery, New York, NY 10021, USA.

ORCID-Profile: Yi Liu

Zitieren

APA

Liu, Y., Walzer, D., Schmitz, S., Shukla, A. P., Ma, X., Chirko, D., Pipia, I., Sathi, S., Shukairy, U., Greenberg, M., Kashyap, S. R., & Stein, E. M. (2026). Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. The Journal of Clinical Endocrinology & Metabolism, 111(7), 1959-1966. https://doi.org/10.1210/clinem/dgag052

Vancouver

Liu Y, Walzer D, Schmitz S, Shukla AP, Ma X, Chirko D, et al. Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. The Journal of Clinical Endocrinology & Metabolism. 2026;111(7):1959-1966. doi:10.1210/clinem/dgag052

BibTeX
@article{Liu2026,
  author = {Liu, Yi and Walzer, Dalia and Schmitz, Sarah and Shukla, Alpana P and Ma, Xiaoyue and Chirko, Dawn and Pipia, Ilissa and Sathi, Swetha and Shukairy, Uthman and Greenberg, Michael and Kashyap, Sangeeta R and Stein, Emily M},
  title = {Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {7},
  pages = {1959--1966},
  doi = {10.1210/clinem/dgag052}
}
Kostenlos starten →